Hong Bin Li

US Patent:

20130072492, Mar 21, 2013

Filed:

May 24, 2011

Appl. No.:

13/699046

Inventors:

Subharekha Raghavan - Teaneck NJ, US
John E. Stelmach - Westfield NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US
Alan Whitehead - Scotch Plains NJ, US
Sherman T. Waddell - Westfield NJ, US
Yi-Heng Chen - Whippany NJ, US
Shouwu Miao - Edison NJ, US
Olga A. Ornoski - Teaneck NJ, US
Joie Garfunkle - Metuchen NJ, US
Xibin Liao - Edison NJ, US
Jiang Chang - Westfield NJ, US
Xiaoqing Han - Edison NJ, US
Jian Guo - Scotch Plains NJ, US
Jonathan A. Groeper - Metuchen NJ, US
Linda L. Brockunier - Orange NJ, US
Keith Rosauer - New Hampton IA, US
Emma R. Parmee - Doylestown PA, US

International Classification:

C07D 487/04
C07D 495/04
A61K 31/5025
A61P 9/00
A61P 9/10
A61P 9/12
A61P 9/04
A61P 7/02
A61P 15/00
A61P 11/06
A61P 13/12
A61P 3/10
A61P 1/16
A61P 9/08
A61P 3/00
A61P 3/06
A61P 7/10
A61K 31/519

US Classification:

514248, 544280, 5142651, 544236, 51425505, 544281, 5142591

Abstract:

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.

US Patent:

20180022747, Jan 25, 2018

Filed:

Feb 12, 2016

Appl. No.:

15/550862

Inventors:

Dongfang MENG - Rahway NJ, US
Hong LI - Rahway NJ, US
Meng YANG - Rahway NJ, US
Manuel de Lera RUIZ - West Point PA, US
Sunita V. DEWNANI - Secaucus NJ, US
Tianying JIAN - Rahway NJ, US
Ting ZHANG - Rahway NJ, US
Louis-Charles CAMPEAU - Rahway NJ, US
Bart HARPER - Rahway NJ, US
Harold B. WOOD - Rahway NJ, US
Jiayi XU - Rahway NJ, US
Richard BERGER - West Point PA, US
Jane Yang WU - Rahway NJ, US
Robert K. ORR - Rahway NJ, US
Shawn P. WALSH - Kenilworth NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 471/04
C07D 403/12
C07D 498/04
C07D 417/14
C07D 513/04
C07D 471/14
C07D 413/14

Abstract:

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

US Patent:

20150342931, Dec 3, 2015

Filed:

Dec 17, 2013

Appl. No.:

14/653445

Inventors:

- Rahway NJ, US
Xiaoxia Qian - New York NY, US
Petr Vachal - Summit NJ, US
Sriram Tyagarajan - Edison NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US
Jianming Bao - Princeton NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/423
A61K 31/4439
C07D 413/14
A61K 45/06
A61K 31/506
A61K 31/5377
C07D 263/52
C07D 413/06
A61K 31/444

Abstract:

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis.